[
  {
    "ts": null,
    "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
    "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
    "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736791802,
      "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
      "id": 132390023,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168184/image_1886168184.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
      "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=fe9c9737072a64d688b33ae454ef5296b94d102c6b3b2bd04542bbff3420e2f1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736785920,
      "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "id": 132408177,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=fe9c9737072a64d688b33ae454ef5296b94d102c6b3b2bd04542bbff3420e2f1"
    }
  },
  {
    "ts": null,
    "headline": "3 Experts Tackle Their 6 'Top Picks' For 2025",
    "summary": "What stocks offer the most profit potential in the new year? Three contributors go into more detail about their six picks for the new year as part of the MoneyShow 'Top Picks' report.",
    "url": "https://finnhub.io/api/news?id=20459c8cd9a4a252574bdb1f51ed6884909d8ae956bed05bf1d731e954d4e168",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736775300,
      "headline": "3 Experts Tackle Their 6 'Top Picks' For 2025",
      "id": 132388948,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2188948847/image_2188948847.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "What stocks offer the most profit potential in the new year? Three contributors go into more detail about their six picks for the new year as part of the MoneyShow 'Top Picks' report.",
      "url": "https://finnhub.io/api/news?id=20459c8cd9a4a252574bdb1f51ed6884909d8ae956bed05bf1d731e954d4e168"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie secures option to license Simcere's blood cancer drug candidate",
    "summary": "-AbbVie has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's unit for markets outside China, in a deal valued at up to $1.06 billion, the companies said...",
    "url": "https://finnhub.io/api/news?id=f63297cc779a747e18fca9765a158377bb1b2a4f0e53ccbe599035aed702f713",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736762047,
      "headline": "AbbVie secures option to license Simcere's blood cancer drug candidate",
      "id": 132387877,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "-AbbVie has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's unit for markets outside China, in a deal valued at up to $1.06 billion, the companies said...",
      "url": "https://finnhub.io/api/news?id=f63297cc779a747e18fca9765a158377bb1b2a4f0e53ccbe599035aed702f713"
    }
  },
  {
    "ts": null,
    "headline": "AbCellera Expands Discovery Partnership With AbbVie",
    "summary": "By Robb M. Stewart AbCellera is expanding its collaboration with pharmaceutical company AbbVie to include the discovery of T-cell engagers in oncology. The new agreement will see the Canadian...",
    "url": "https://finnhub.io/api/news?id=36a150acc2f8ee4e2695ddca204944cee3b6100b3f2d51d7190813e0b1af8378",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736761093,
      "headline": "AbCellera Expands Discovery Partnership With AbbVie",
      "id": 132387719,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Robb M. Stewart AbCellera is expanding its collaboration with pharmaceutical company AbbVie to include the discovery of T-cell engagers in oncology. The new agreement will see the Canadian...",
      "url": "https://finnhub.io/api/news?id=36a150acc2f8ee4e2695ddca204944cee3b6100b3f2d51d7190813e0b1af8378"
    }
  },
  {
    "ts": null,
    "headline": "China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate",
    "summary": "Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer drug candidate outside China. Under the deal, AbbVie will pay...",
    "url": "https://finnhub.io/api/news?id=bea0539db45c4924f8442720630fc7af141eca92da383d281c94350551935927",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736759870,
      "headline": "China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate",
      "id": 132387622,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer drug candidate outside China. Under the deal, AbbVie will pay...",
      "url": "https://finnhub.io/api/news?id=bea0539db45c4924f8442720630fc7af141eca92da383d281c94350551935927"
    }
  }
]